Merck grabs FDA green light for less-frequent Keytruda dosing regimen

That didn’t take long. Just days after resubmitting its application to the FDA, Merck nabbed an approval Tuesday for a new, more convenient Keytruda dosing regimen

The FDA green light cleared the immuno-oncology blockbuster for use every six weeks—rather than every three—across all of Keytruda’s approved indications, on its own and in combination with other meds.